SLC5A2 and neoplasm: Though clinical trials are mostly novel and ongoing, harnessing the pleiotropic effects of SGLT2 inhibitors creates new avenues for research and insight into evolving cancer therapies that may reduce tumor growth and impart diabetic and cardiac profiles while improving patient outcomes.